Literature DB >> 12432560

Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland.

Salla Kumpulainen1, Seija Grénman, Pentti Kyyrönen, Eero Pukkala, Risto Sankila.   

Abstract

To assess the effect of different hospital types or surgical volume on the survival of ovarian cancer patients, a nationwide and population-based analysis was carried out in Finland. The study included all 3,851 ovarian cancer patients operated from 1983-94. The patients were classified according to the hospital of the first surgery. The hospitals were categorized by type (university, central or other hospital) and, separately, into quartiles by the number of operated patients (surgical volume). The patients operated at university hospitals had better survival than those operated in central hospitals, the 5-year relative survival rates (RSR) being 45% (95% CI = 42-48%) and 37% (34-40%), respectively. RSR in the 'other hospital' category was 45% (42-48%). The RSR for the patients operated in the highest volume hospitals was 47% (43-50%), and by decreasing volume (quartile) the RSR was 40% (36-43%), 40% (36-43%) and 42% (38-45%), respectively. After controlling for potential confounding by stage and age using regression models, the results remained practically the same. The results indicate that further centralizing of operative treatment of ovarian cancer may still improve survival rates on a population level in Finland. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12432560     DOI: 10.1002/ijc.10754

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Authors:  Lele Shashikant; P Kesterson Joshua
Journal:  J Obstet Gynaecol India       Date:  2009 May-Jun

2.  Prognostic impact of hospital volume on familial adenomatous polyposis: a nationwide multicenter study.

Authors:  Masahiro Tanaka; Yukihide Kanemitsu; Hideki Ueno; Hirotoshi Kobayashi; Tsuyoshi Konishi; Fumio Ishida; Tatsuro Yamaguchi; Takao Hinoi; Yasuhiro Inoue; Naohiro Tomita; Hideyuki Ishida; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2017-08-22       Impact factor: 2.571

Review 3.  Centralisation of services for gynaecological cancer.

Authors:  Yin Ling Woo; Maria Kyrgiou; Andrew Bryant; Thomas Everett; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

4.  Development of a nomogram for predicting survival of patients with ovarian serous cystadenocarcinoma after based on SEER database.

Authors:  Xiaobin Chen; Tingting Guo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

5.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

6.  Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study.

Authors:  Stephanie Ricci; Ana I Tergas; Kara Long Roche; Melissa Gerardi Fairbairn; Kimberly L Levinson; Sean C Dowdy; Robert E Bristow; Micael Lopez; Katrina Slaughter; Kathleen Moore; Amanda N Fader
Journal:  Gynecol Oncol Rep       Date:  2017-11-15

7.  High-Volume Hospitals' Ovarian Cancer Care-Less Individual Approach or Better Treatment Results?

Authors:  Sonja Millert-Kalińska; Dominik Pruski; Marcin Przybylski; Małgorzata Stawicka-Niełacna; Edyta Mądry; Radosław Mądry
Journal:  Curr Oncol       Date:  2022-07-26       Impact factor: 3.109

8.  An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear.

Authors:  Vincenzo Dario Mandato; Federica Torricelli; Stefano Uccella; Debora Pirillo; Gino Ciarlini; Gabriele Ruffo; Gianluca Annunziata; Gloria Manzotti; Sandro Pignata; Lorenzo Aguzzoli
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.